Skip to main content
Clinical Trials/NCT04115527
NCT04115527
Active, not recruiting
Not Applicable

A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer

Ruijin Hospital1 site in 1 country100 target enrollmentJune 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreatic Ductal Adenocarcinoma
Sponsor
Ruijin Hospital
Enrollment
100
Locations
1
Primary Endpoint
3 years overall survival rate
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to determine whether para-aortic lymph nodes(No.16) should be included in the lymphadenectomy during the pancreatoduodenectomy in order to improve the long-term survival of patients with pancreatic head ductal adenocarcinoma.

Detailed Description

Pancreatic cancer is now raised to the 7th leading cause of death. Surgical resection seems to be the unique curative therapy for pancreatic cancer. The pancreaticoduodenectomy is widely performed for the patients with pancreatic head cancer in recent decades. The lymphadenectomy is an indispensible procedure. In 2014, the International Study Group for Pancreatic Surgery (ISGPS) recommended a standard lymphadenectomy should include lymph node stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b. However, no consensus was reached on Lymph node 16 in particular 16b1. There was no stronge evidence available concerning the impact on survival.

Registry
clinicaltrials.gov
Start Date
June 1, 2018
End Date
December 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Weishen WANG

Principal Investigator

Ruijin Hospital

Eligibility Criteria

Inclusion Criteria

  • Pathologic diagnosis of pancreatic ductal adenocarcinoma
  • Signed the informed consents

Exclusion Criteria

  • Pathologic diagnosis of other pancreatic cancers
  • Pre-operative anti-cancer treatment
  • Recurrence patients
  • Patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc )
  • Pre operative exam: Total bilirubin more than 250µmol/L
  • AJCC stage IV
  • Operation non radical

Outcomes

Primary Outcomes

3 years overall survival rate

Time Frame: 3 years post-operation

3 years overall survival rate

5 years overall survival rate

Time Frame: 5 years post-operation

5 years overall survival rate

1 year overall survival rate

Time Frame: 1 year post-operation

1 year overall survival rate

Secondary Outcomes

  • Postoperative Complications(Within 90 days or before discharge)
  • 1, 3 & 5 years disease free survival rate(1, 3 & 5 years post-operation)

Study Sites (1)

Loading locations...

Similar Trials